2026 GLP-1 Weight Loss Guidelines: What Patients Should Know About Semaglutide, Tirzepatide, and Medical Weight Loss
August 31, 2026
Weight-loss medicine continues to evolve quickly, but one message is becoming increasingly clear: effective medical weight management is about much more than getting a prescription.
In 2026, the American College of Physicians published a new living clinical guideline on medications for adults with overweight or obesity. Among its most notable recommendations, the guideline identifies semaglutide and tirzepatide as first-line pharmacologic options for certain adults with obesity when medication is used alongside lifestyle modifications. The recommendations also emphasize individual health conditions, treatment goals, potential harms, cost, access, contraindications, and patient preferences when deciding whether medication is appropriate. You can review the 2026 ACP guideline on PubMed.
For patients considering GLP-1 or GLP-1/GIP medications, the takeaway is not simply that these medications work. It is that medical weight loss is becoming more individualized, medically supervised, and focused on long-term health rather than the number on the scale alone.
What Changed in the 2026 Weight-Loss Guidelines?
The American College of Physicians guideline addresses medication treatment for nonpregnant adults with overweight or obesity in outpatient care.
For adults with a BMI of 30 kg/m2 or greater, the ACP suggests pharmacologic treatment together with lifestyle modifications when treatment is appropriate. Within the medications evaluated, semaglutide and tirzepatide were identified as first-line options, with moderate-certainty evidence supporting the recommendations.
The guideline also considers medication treatment for adults with a BMI between 27 and 30 kg/m2 who have certain weight-related health conditions, including type 2 diabetes, high cholesterol or other dyslipidemia, hypertension, obstructive sleep apnea, or cardiovascular disease. For this group, semaglutide and tirzepatide were again listed among the first-line pharmacologic options.
This does not mean everyone with a BMI above a particular number should receive a GLP-1 medication.
Instead, the guideline specifically encourages clinicians and patients to consider factors such as medical history, weight-related conditions, treatment goals, side effects, contraindications, cost, access, and individual preferences before choosing a medication.
That distinction matters.
Semaglutide and Tirzepatide Are Similar, but They Are Not the Same
The terms “GLP-1” and “weight-loss injection” are often used interchangeably online, but the medications within this category work differently.
Semaglutide is a GLP-1 receptor agonist. GLP-1 signaling helps regulate appetite, food intake, and blood glucose.
Tirzepatide activates both GLP-1 and glucose-dependent insulinotropic polypeptide, or GIP, receptors.
For chronic weight management, the FDA has approved tirzepatide under the brand name Zepbound for eligible adults with obesity or adults with overweight who also have at least one weight-related condition. It is intended to be used together with reduced-calorie nutrition and increased physical activity. The FDA’s Zepbound approval information provides more details.
Semaglutide, sold for weight management as Wegovy, is also FDA-approved for long-term weight management in eligible patients. It additionally carries an FDA-approved indication to reduce cardiovascular death, heart attack, and stroke in certain adults who have established cardiovascular disease and overweight or obesity. More details are available through the FDA’s Wegovy cardiovascular approval announcement.
In March 2026, the FDA also approved a higher 7.2 mg dose of Wegovy injection for certain adults, another example of how quickly obesity treatment options continue to develop. Read the FDA’s March 2026 announcement.
The appropriate medication and dose, however, depend on the individual.
Why Medical Supervision Matters With GLP-1 Treatment
One of the biggest misconceptions surrounding GLP-1 weight loss is that treatment consists of simply receiving an injection every week.
A medically guided weight-loss program should involve considerably more.
Before treatment, a provider may review your:
- Current weight and weight history
- Medical conditions
- Current medications and supplements
- Previous weight-loss attempts
- Blood pressure and metabolic risk factors
- Family and personal medical history
- Nutrition and activity patterns
- Laboratory results when clinically appropriate
This type of assessment helps determine not only whether someone may qualify for medication, but also which treatment options make sense and what should be monitored.
At BelleVie Wellness Care’s Medical Weight Loss program, care may include a health-history review, laboratory evaluation when appropriate, nutrition and lifestyle guidance, treatment planning, and ongoing progress monitoring.
GLP-1 Medication Still Goes Together With Lifestyle Care
The 2026 ACP recommendations are important partly because they reinforce something sometimes lost in social-media conversations about weight-loss medication: pharmacologic treatment and lifestyle treatment are not competing strategies.
The ACP guideline specifically recommends medication with lifestyle modifications, rather than medication as a replacement for them.
Other clinical guidance has reached similar conclusions. Expert recommendations for people using GLP-1-based therapies emphasize individualized physical activity, appropriate nutrition, resistance exercise, and ongoing monitoring as part of comprehensive weight management.
That can include attention to:
Nutrition. Reduced appetite may make it easier to consume fewer calories, but eating less does not automatically mean eating well. Protein, fiber, hydration, vitamins, minerals, and overall dietary quality still matter.
Strength and movement. Weight loss can include loss of both fat mass and lean tissue. A 2026 systematic review found that incorporating resistance training during weight reduction may help preserve lean mass better than weight-loss interventions without resistance training. Read the 2026 lean-mass systematic review on PubMed.
Sleep and stress. Sleep quality, mood, stress, and daily routines can influence eating patterns, activity, and long-term consistency.
Follow-up. Weight-management medications may require gradual dose adjustments, assessment of side effects, and ongoing decisions about whether the current plan remains appropriate.
This is why provider-guided care can look very different from a one-size-fits-all online weight-loss program.
What About GLP-1 Side Effects?
GLP-1 and GLP-1/GIP medications can cause side effects, and treatment is not appropriate for everyone.
Commonly reported gastrointestinal side effects can include nausea, vomiting, diarrhea, constipation, and abdominal discomfort. Depending on the medication and a person’s medical history, clinicians may also need to consider risks involving the gallbladder, pancreas, kidneys, blood glucose, or other conditions. Some products also carry a boxed warning related to thyroid C-cell tumors observed in animals and are contraindicated in people with certain personal or family histories.
This is another reason why patients should discuss their complete medical and medication history with a qualified healthcare provider rather than selecting treatment based primarily on social-media recommendations or someone else’s results.
A 2026 Safety Issue Patients Should Know About: Unapproved GLP-1 Products
As demand for GLP-1 medications has grown, the FDA has also increased its attention to unapproved and fraudulently marketed products.
In an updated 2026 safety communication, the FDA reported concerns involving fraudulent compounded semaglutide and tirzepatide products, dosing errors, varying concentrations, and products marketed with misleading information. The agency states that compounded medications do not undergo the same FDA premarket review for safety, effectiveness, and quality as FDA-approved medications. Read the FDA’s current GLP-1 safety information.
That does not mean compounding is never medically appropriate. There are circumstances in which federal law permits compounded medications for specific patient needs. It does mean patients should know exactly what medication they are receiving, where it comes from, how it should be measured, and how the prescribed dose should be administered.
If your medication comes in a vial and requires you to measure a dose yourself, ask questions until the instructions are completely clear.
What Should You Ask Before Starting GLP-1 Weight Loss?
A medical weight-loss consultation is an opportunity to look beyond “Can I take this medication?”
Useful questions include:
- Am I actually a good candidate for medical weight-loss medication?
- Which medication makes the most sense based on my medical history?
- Are there medications or health conditions that could affect my treatment?
- Do I need laboratory testing before or during treatment?
- What side effects should I expect, and when should I contact my provider?
- How will my dose be adjusted?
- How should I approach protein, nutrition, hydration, and exercise?
- How often will my progress be reviewed?
- What is the long-term plan if I reach my weight goal?
Those questions reflect an important shift in modern obesity medicine.
The goal is not simply to lose weight quickly. The goal is to find a treatment strategy that makes sense for your health and can be monitored safely over time.
The Bottom Line
The new 2026 ACP recommendations reinforce how far medical weight management has progressed. Semaglutide and tirzepatide now have a prominent place among evidence-based pharmacologic options for appropriately selected adults, but medication remains only one part of the picture.
The most effective approach is increasingly a whole-person approach: appropriate medication when indicated, nutrition, movement, metabolic health, clinical monitoring, and a plan that can evolve as your health and goals change.
For patients, that may be the most important GLP-1 development of all.
BelleVie Wellness Care Can Help
BelleVie Wellness Care offers GLP-1/GIP Therapy and Medical Weight Loss in Hollywood, Florida, with provider-guided evaluation, laboratory screening when appropriate, individualized treatment planning, and ongoing follow-up monitoring.
If you are considering GLP-1 or GLP-1/GIP therapy and want to better understand your options, a consultation can help you understand what treatment plan makes sense for your health and goals.
Medical Disclaimer
This article is provided for informational and educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease or medical condition. It does not constitute individualized medical advice and should not replace consultation with a qualified healthcare professional. GLP-1 and GLP-1/GIP medications are prescription treatments and are not appropriate for everyone. Eligibility, medication selection, dosing, monitoring, potential risks, and expected benefits should be determined by a licensed healthcare provider after reviewing an individual’s medical history, medications, laboratory findings when appropriate, and other relevant clinical factors. Treatment results vary from person to person. If you have questions about a medication or weight-management treatment, consult your healthcare provider.